Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 25.01.2022 at 12:00 PM CET
Settings

Settings

Goto Application

1. WO2022010955 - METHODS OF TREATING COVID-19 PATHOGENESIS

Publication Number WO/2022/010955
Publication Date 13.01.2022
International Application No. PCT/US2021/040593
International Filing Date 07.07.2021
IPC
A61K 9/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
A61K 31/522 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519ortho- or peri-condensed with heterocyclic rings
52Purines, e.g. adenine
522having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
A61K 38/48 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
43Enzymes; Proenzymes; Derivatives thereof
46Hydrolases (3)
48acting on peptide bonds (3.4)
A61K 45/06 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 31/14 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
C07K 16/10 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Applicants
  • UT-BATTELLE, LLC [US]/[US]
  • JACOBSON, Daniel A. [US]/[US]
  • PRATES, Erica Teixeira [US]/[US]
  • MILLER, John I. [US]/[US]
  • GARVIN, Michael [US]/[US]
Inventors
  • JACOBSON, Daniel A.
  • PRATES, Erica Teixeira
  • MILLER, John I.
  • GARVIN, Michael
Agents
  • GROLZ, Edward W.
Priority Data
63/048,70907.07.2020US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) METHODS OF TREATING COVID-19 PATHOGENESIS
(FR) MÉTHODES DE TRAITEMENT DE LA PATHOGENÈSE DE LA COVID-19
Abstract
(EN) This disclosure provides methods for treating a SARS-CoV-2 infection in a subject comprising administering to the subject an effective amount of an inhibitor of COVIDinduced RAS imbalance, that downregulates, for example, the Bradykinin system, the Renin-Angiotensin system, the hyaluronan synthesis pathway, or the fibrinogenesis pathway.
(FR) La présente divulgation concerne des méthodes de traitement d'une infection à SARS-CoV-2 chez un sujet, comprenant l'administration au sujet d'une quantité efficace d'un inhibiteur du déséquilibre du SRA induit par la maladie, qui régule à la baisse, par exemple, le système bradykinine, le système rénine-angiotensine, la voie de synthèse du hyaluronane, ou la voie de la fibrinogenèse.
Latest bibliographic data on file with the International Bureau